Literature DB >> 2511756

Quinolone resistance. Susceptibility data from a 300-bed community hospital.

M F Parry1, K B Panzer, M E Yukna.   

Abstract

Introduction of the fluoroquinolones has altered physician prescribing practices in the treatment of infectious diseases for both inpatients and outpatients. To evaluate the impact of unrestricted prescribing of these agents, the antimicrobial susceptibility of clinical isolates to ciprofloxacin and other commonly used antibiotics was prospectively studied in a 300-bed community teaching hospital. Only 0.6 percent (nine of 1,454 isolates) of fresh clinical isolates were resistant to ciprofloxacin (minimal inhibitory concentration value greater than 2 micrograms/ml) in an initial study conducted between 1984 and 1985. A similar pattern was observed in the second half of 1987 (0.5 percent, or five of 940 isolates), just prior to the release of ciprofloxacin. Throughout 1988, however, as quinolone usage rose, the incidence of ciprofloxacin resistance rose, reaching a peak of 4.0 percent in the last quarter of 1988. Of 63 ciprofloxacin-resistant isolates in 1988, 22 were Pseudomonas and 28 were staphylococci, representing resistance rates of 6.5 and 4.2 percent, respectively. Enterobacteriaceae remained exquisitely susceptible with only five of 1,720 isolates (0.3 percent) resistant to ciprofloxacin. Seventy-two percent of ciprofloxacin-resistant isolates were recovered from patients who had received a fluoroquinolone within the previous month. If these isolates are subtracted from the total number of resistant micro-organisms recovered, baseline fluoroquinolone resistance did not change significantly from 1984 to 1988. Soft-tissue infections (50 percent) represented the greatest source of ciprofloxacin-resistant organisms, including osteomyelitis, but urinary tract infections (26 percent), all associated with instrumentation, were also a significant source. Although the fluoroquinolones are extremely valuable antimicrobial agents, the emergence of drug resistance may be promoted when these drugs are used for treatment of chronic infections or when poorly drained abscesses, necrotic tissue, or indwelling foreign bodies are present.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2511756     DOI: 10.1016/0002-9343(89)90012-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  10 in total

1.  Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.

Authors:  G Siami; N Christou; I Eiseman; K J Tack
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 2.  Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  J A Balfour; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

3.  Penetration of ciprofloxacin into the human pancreas.

Authors:  R Isenmann; H Friess; P Schlegel; K Fleischer; M W Büchler
Journal:  Infection       Date:  1994 Sep-Oct       Impact factor: 3.553

4.  Canadian ciprofloxacin susceptibility study: comparative study from 15 medical centers. Canadian Ciprofloxacin Study Group.

Authors:  J M Blondeau; Y Yaschuk
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

Review 5.  Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.

Authors:  L R Wiseman; J A Balfour
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

6.  Therapeutic efficacy of "nubiotics" against burn wound infection by Pseudomonas aeruginosa.

Authors:  Roderic M K Dale; Glen Schnell; Jonathan P Wong
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

7.  Prevalence of ciprofloxacin resistance in multiresistant gram-negative intensive care unit isolates.

Authors:  C M Khurana; B R Wojack
Journal:  Infection       Date:  1994       Impact factor: 3.553

8.  Antibiotic resistance of Escherichia coli in fecal samples of healthy people in two different areas in an industrialized country.

Authors:  M Bonten; E Stobberingh; J Philips; A Houben
Journal:  Infection       Date:  1992 Sep-Oct       Impact factor: 3.553

Review 9.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

Review 10.  Do we need an intravenous fluoroquinolone?

Authors:  D S Maddix; L Warner
Journal:  West J Med       Date:  1992-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.